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The Epstein-Barr virus (EBV) is associated with AIDS-
induced lymphomas and Kaposi's sarcoma, and in most
patients with these tumors, the viral genome serves as a
nearly tumor-specific target. BETR therapy proposes to use
Bortezomib to induce Epstein-Barr virus (EBV)-thymidine
kinase (TK) expression, which can be targeted with iodine
labeled 2'-fluoro-2'-deoxy-beta-D-5-iodouracil-arabino-
furanoside (FIAU). Monte Carlo is an established proce-
dure for simulating radioactive decay and obtaining the
absorbed dose distribution from a spatial configuration of
radionuclide decays. We present here the Monte Carlo
simulation and dosimetry modeling of spherical tumors
using GEANT4 for BETR to examine the issue of efficacy
relative to percentage of cells induced to express viral TK,
in particular for a level of 1 percent, which is the typical
percentage of virally infected tumor cells for the AIDS-
induced lymphomas.
We constructed a spherical tumor model of spherical cells
(15 μm diameter) in a hexagonal lattice of varying sizes
(~10, 20, 50, and 150 cells per side). 131I is randomly
allowed to decay according to three different models with
varying degrees of 131I cell uptake: 100 percent of cells, 10
percent of cells, and 1 percent of cells containing 131I. The
energy deposited in each cell is collected and the dose to
each cell calculated. Validation was performed, in part, by
checking the MC-derived distribution of decaying 131I
within the cells, and the spatial distribution of cells.
The model can be scaled to the tumor size by maintaining
the correct ratio of decaying particles to cells and by
increasing the amount of deposited energy per decay. The
scaling factor comes from simple spherical modeling
results, and reflects the fact that the ionizing particles have
more distance to deposit energy as the tumor size
increases. Also due to the large energy deposition range of
131I (~1 mm) compared to the cell size, we observe little
difference in the dose distribution per cell between the
different percentages of active cells.
The analysis suggests that potential therapeutic efficacy, as
measured by the mean absorbed dose and spatial dose
distribution in the tumor will be independent of the frac-
tion of cells in the tumor that express viral TK and concen-
trate 131I-FIAU. The development of a kinetic model is the
next step in this effort to assist in assessing the feasibility
of porting Bortezomib-induced viral TK uptake of 131I-
FIAU to clinical trials. The kinetic model features multi-
step kinetics including Bortezomib uptake, TK expression
and [131I]FIAU absorption and retention.
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